Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Cancer ◽  
2021 ◽  
Author(s):  
Vadim S. Koshkin ◽  
Nicholas Henderson ◽  
Marihella James ◽  
Divya Natesan ◽  
Dory Freeman ◽  
...  
Keyword(s):  
Urothelial Cancer ◽  
Advanced Urothelial Cancer ◽  
Therapeutic Experiences ◽  
Cancer Network

Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 443-443
Author(s):  
Vadim S Koshkin ◽  
Yilun Sun ◽  
Dory Freeman ◽  
Chelsea K. Osterman ◽  
Christopher Su ◽  
...  
Keyword(s):  
Urothelial Cancer ◽  
Objective Response ◽  
Standard Of Care ◽  
Antibody Drug Conjugate ◽  
Histological Variants ◽  
Variant Histology ◽  
Advanced Urothelial Cancer ◽  
Definitive Surgery ◽  
Ecog Ps ◽  
Cancer Network

443 Background: Enfortumab vedotin (EV) is an antibody-drug conjugate targeting Nectin-4, which is FDA approved for patients (pts) with treatment-refractory advanced urothelial cancer (aUC). The activity of EV in pt subsets of interest such as those with distinct histological variants has not been well defined. Methods: A retrospective study of pts with aUC treated with ≥1 dose of EV as standard of care (SOC) or on a clinical trial (if trial results already reported) at 12 US sites was undertaken. Objective response rate (ORR) was investigator-assessed for pts with at least one post-baseline scan or clear evidence of clinical progression. ORR was compared across subsets of interest using proportion test. Results: A total of 184 patients with aUC were included; median age at diagnosis 70, 20% women and 60% with definitive surgery. Most common primary sites included bladder (70%) and upper tract (28%). Majority of pts (72%) had pure urothelial histology (UH) per local review, but 26% had at least a component of variant histology (VH), most commonly squamous (14%), micropapillary (8%) or plasmacytoid (3%). EV was given as monotherapy in 84% and as SOC in 58%; and 81% had ≥ 1 prior treatment in the metastatic (met) setting. ECOG PS was ≥2 in 15%; 37% had baseline neuropathy, 15% diabetes and 9% had GFR≤30. At median follow-up of 37.0 (IQR: 20.5-60.2) months from initial diagnosis, median time from met diagnosis to EV start was 11.7 (IQR: 4.3 – 20.5) months. Median duration of EV was 5.5 (IQR: 1.4 – 6.7) months, and 84% of pts were evaluable for response. ORR for evaluable pts was 53% (8% CR, 45% PR); 25% had SD and 21% PD. Median PFS and OS were not yet reached. At data cutoff in 9/2020, 55% had stopped EV (36% due to PD, 19% intolerance) and 65% were alive. Comparison of ORR in subgroups of interest for 127 evaluable pts treated with EV monotherapy is shown in the table below. Notably, among 31 pts with FGFR3 alterations, 26 were evaluable and ORR was 46%. Conclusions: In a large, retrospective, multi-institutional cohort, responses to EV were observed across a broad range of aUC pts, including pts with variant histology component, FGFR3 alterations and also in populations previously excluded from clinical trials such as pts with GFR<30 and significant baseline comorbidities. No significant differences in ORR were demonstrated for patient subsets of interest. [Table: see text]

Sequential therapies for advanced urothelial cancer: Hope meets new challenges

2021 ◽  
pp. 103248
Author(s):  
Daniel Herchenhorn ◽  
Vinicius Freire ◽  
Thamires Oliveira ◽  
Juliana Tarouquella
Keyword(s):  
Urothelial Cancer ◽  
New Challenges ◽  
Advanced Urothelial Cancer

A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer

1995 ◽  
Vol 35 (5) ◽  
pp. 391-396 ◽  
Author(s):  
Etienne Chatelut ◽  
Christine Chevreau ◽  
Valérie Brunner ◽  
Mathilde Martinez ◽  
Georges Houin ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Urothelial Cancer ◽  
Advanced Urothelial Cancer

Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer

2013 ◽  
Vol 31 (4) ◽  
pp. 1001-1007 ◽  
Author(s):  
Robert Jones ◽  
Jacqueline Vuky ◽  
Tony Elliott ◽  
Graham Mead ◽  
José Angel Arranz ◽  
...  
Keyword(s):  
Phase Ii ◽  
Mitotic Spindle ◽  
Urothelial Cancer ◽  
Phase Ii Study ◽  
Advanced Urothelial Cancer

Carboplatin, Methotrexate and Vinblastin (Carbo-MV) for Advanced Urothelial Cancer A Phase II Trial

1991 ◽  
Vol 14 (4) ◽  
pp. 328-330 ◽  
Author(s):  
J. Klocker ◽  
J. Pont ◽  
J. Schumer ◽  
J. Prüger ◽  
H. Kienzer
Keyword(s):  
Phase Ii ◽  
Urothelial Cancer ◽  
Phase Ii Trial ◽  
Advanced Urothelial Cancer

Neoadjuvant Chemotherapy for Locally Advanced Urothelial Cancer of the Upper Urinary Tract

1995 ◽  
Vol 55 (2) ◽  
pp. 74-77 ◽  
Author(s):  
M. Igawa ◽  
S. Urakami ◽  
H. Shiina ◽  
H. Kishi ◽  
Y. Himeno ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Neoadjuvant Chemotherapy ◽  
Urothelial Cancer ◽  
Locally Advanced ◽  
Upper Urinary Tract ◽  
Advanced Urothelial Cancer
Sign in / Sign up

Export Citation Format

Share Document